- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00336063
Vorinostat a azacitidin při léčbě pacientů s lokálně recidivujícím nebo metastatickým karcinomem nosohltanu nebo nazálním přirozeným zabijáckým T-buněčným lymfomem
Studie fáze I s 5azacitidinem a suberoylanilid hydroxamovou kyselinou u pacientů s metastatickým nebo lokálně recidivujícím karcinomem nosohltanu a nosním lymfomem z NK-T buněk
This phase I trial studies the side effects and best dose of vorinostat when given together with azacitidine in treating patients with nasopharyngeal cancer or nasal natural killer T-cell lymphoma that has recurred (come back) at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or has spread to other parts of the body. Drugs used in chemotherapy, such as vorinostat and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vorinostat and azacitidine also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with azacitidine may kill more cancer cells.
Přehled studie
Postavení
Podmínky
- Recidivující nasofaryngeální keratinizující spinocelulární karcinom
- Recidivující nasofaryngeální nediferencovaný karcinom
- Stádium IV nasofaryngeální keratinizující spinocelulární karcinom AJCC v7
- Extranodální lymfom NK/T-buněk nosního typu u dospělých
- Stádium IV nasofaryngeálního nediferencovaného karcinomu AJCC v7
Detailní popis
PRIMARY OBJECTIVES:
I. Define toxicity profile of escalating doses of suberoylanilide hydroxamic acid (SAHA) given in conjunction with a fixed dose of 5 Azacytidine (5AC) (azacitidine) in patients with locally recurrent and metastatic nasopharyngeal carcinoma and natural killer (NK)-T cell nasal lymphoma.
II. Define the biologically optimal dose of SAHA given in conjunction with a fixed dose of 5AC in patients with locally recurrent and metastatic nasopharyngeal carcinoma and NKT cell nasal lymphoma based on evidence of Epstein-Barr virus (EBV) lytic induction in tumor biopsies and plasma.
III. Study the effect of 5AC on the pharmacokinetic of SAHA in patients with locally recurrent and metastatic nasopharyngeal carcinoma and NK-T cell nasal lymphoma.
IV. Assess the effect of SAHA on histone acetylation as measured in tumor and peripheral blood mononuclear cells of patients with locally recurrent and metastatic nasopharyngeal carcinoma and NK-T cell nasal lymphoma V. Assess the effect of 5AC on EBV promoter demethylation as measured in tumor patients with locally recurrent and metastatic nasopharyngeal carcinoma and NK-T cell nasal lymphoma.
OUTLINE: This is a dose-escalation study of vorinostat (SAHA).
Patients receive azacitidine subcutaneously (SC) on days 1-10 and vorinostat orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients with responding disease may continue treatment at the discretion of the principal investigator. Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
-
Shatin, Hongkong
- Chinese University of Hong Kong-Prince of Wales Hospital
-
-
-
-
-
Tokyo, Japonsko, 104 0045
- National Cancer Center Hospital
-
-
-
-
-
Singapore, Singapur, 119074
- National University Hospital Singapore
-
Singapore, Singapur, 168583
- National Cancer Centre Singapore
-
-
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Biopsy proven nasopharyngeal carcinoma (World Health Organization [WHO] type 3) or extranodal NK-T-cell non-Hodgkin's lymphoma, nasal type (recurrence or metastases does not require tissue documentation)
- Patients must have metastatic disease or locally recurrent disease that is not amendable to surgical resection
- Patients must have locally recurrent disease that is not amendable to further treatment with radiotherapy with curative intent
- Patients must have metastatic disease or locally recurrent disease that has been treated with at least one regimen of chemotherapeutic agents after relapse; patient must be at least 4 weeks since prior chemotherapy or radiation therapy
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy greater than 6 months
- Leukocytes >= 3,000/ul
- Absolute neutrophil count >= 1,500/ul
- Platelets >= 100,000/ul
- Total bilirubin =< 1.5 X normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Prothrombin time =< 1.5 X normal institutional limits
- Serum albumin >= 2.7 grams/deciliter
- Creatinine =< 1.5 X normal institutional limits or a calculated creatinine clearance of > 50 mls/min
- Sexually active women of child-bearing potential should have a negative serum or urine pregnancy test within 21 days of enrolling on trial; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Patients must be informed of the investigational nature of the treatment, results that might be expected, and potential toxicities; they must be able to give informed written consent according to federal and institutional guidelines
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients may not be receiving any other investigational agents
- Patients with known central nervous system (CNS) involvement (brain metastases or carcinomatous meningitis should be excluded from this clinical trial; patients with skull base involvement are eligible for this study
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to 5AC or SAHA
- Patients should not have taken sodium valproate for at least 2 weeks prior to enrollment
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with 5AC and SAHA
- Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study
- Patients with chronic active hepatitis B are excluded from the study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Treatment (azacitidine, vorinostat)
Patients receive azacitidine SC on days 1-10 and vorinostat PO BID on days 1-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. |
Correlative studies Correlative studies Given SC
Ostatní jména:
Given PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Maximum tolerated dose of vorinostat and azacitidine, defined as the dose at which less than one-third of patients experience a dose limiting toxicity (i.e., fewer than 2 of 6 patients)
Časové okno: Day 28
|
Graded according to the National Cancer Institute/Division of Cancer Treatment Common Toxicity Criteria. |
Day 28
|
|
Precision of the estimated dose-response curve based on induction of lytically replicated viral particles in the plasma following treatment
Časové okno: Up to 16 weeks
|
A non-parametric and a parametric approach will be used. The non-parametric approach will entail averaging the biologic effects from the patients at each time point, plotting them versus dose, and connecting the points to get the dose-response curve. The parametric approach will use a polynomial regression model with two degrees of freedom for modeling dose. A spline model may also be used. |
Up to 16 weeks
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Pharmacokinetics of vorinostat in patients with locally recurrent and metastatic nasopharyngeal carcinoma and NK-T cell nasal lymphoma
Časové okno: 0, 15, 45, 60, 120, 180, 270, 360, and 480 minutes on days 1 and 14 of course 1
|
Performed using a validated high performance liquid chromatography method. Maximum concentration (Cmax) and time to Cmax will be read off the curve, terminal T1/2 will be derived using the slope of the terminal portion of the semilogarithmic concentration-time plot, incorporating at least 3 time points in the extrapolation of the curve. Area-under-the curve (AUC) (infinity) of the semilog plot will be estimated using the trapezoidal method, and oral clearance (CL/F) will be derived using Dose/AUC, volume of distribution will be calculated. |
0, 15, 45, 60, 120, 180, 270, 360, and 480 minutes on days 1 and 14 of course 1
|
|
Proportions of patients with high and low histone acetylation
Časové okno: Baseline
|
The proportion of patients whose histone acetylation status changes in each group will be estimated with its 95% confidence interval. Percent agreement and kappa will be used. |
Baseline
|
|
EBV promoter demethylation as measured in tumor patients with locally recurrent and metastatic nasopharyngeal carcinoma and NK-T cell nasal lymphoma
Časové okno: Baseline
|
The proportion of patients whose EBV promoter demethylation status changes in each group will be estimated with its 95% confidence interval. Percent agreement and kappa will be used. |
Baseline
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Wen-Son Hsieh, Johns Hopkins Singapore
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary
- Novotvary podle histologického typu
- Lymfom, Non-Hodgkin
- Lymfom
- Lymfom, T-buňka
- Lymfom, extranodální NK-T-buňka
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Nukleové kyseliny, nukleotidy a nukleosidy
- Karboxylové kyseliny
- Hydroxy kyseliny
- Anilides
- Amidy
- Anilinové sloučeniny
- Aminy
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Aza sloučeniny
- Nukleosidy
- Ribonukleosidy
- Kyseliny hydroxamové
- Hydroxylaminy
- Vorinostat
- Azacitidin
Další identifikační čísla studie
- NCI-2009-00089
- P30CA006973 (Grant/smlouva NIH USA)
- NCI-2009-00089 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- NCI-6837
- CTRG NP03/19/04 (Jiný identifikátor: Johns Hopkins Singapore)
- CDR0000472702
- 6837 (Jiný identifikátor: CTEP)
- CTRG NP03/19/04
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .